The American College of Rheumatology (ACR) published 2 updated guidelines for juvenile idiopathic arthritis (JIA) treatment and management.^1,2 The first guideline discusses nonpharmacologic therapies, medication monitoring, immunizations, and imaging, regardless of the JIA phenotype.¹ The second guideline mainly provides updates for pharmacologic management of JIA, precisely focusing on the treatment of temporomandibular joint (TMJ) arthritis, oligoarthritis and systemic JIA, regardless of the macrophage activation syndrome (MAS).²

Osteoarthritis is a leading cause of disability and a source of societal cost in the elderly that is becoming more prevalent especially with increasing obesity and number of joint injuries.¹ The findings of a recent milestone meta-analysis deciphering the genetics of knee, hip, finger, thumb, and spine osteoarthritis across 826,690 individuals of European and East Asian descent, of whom 177,517 have osteoarthritis, were recently published in CELL.² This study identified 52 previously unknown osteoarthritis genetic risk variants including SOX5 and CHST3 genes, overlapping genetic components in different osteoarthritis subtypes and pathology, and an association between the genetic components and pain-related phenotypes and other traits, providing insight into the key molecular players as potential drug targets.²